Breaking News Instant updates and real-time market news.

APVO

Aptevo Therapeutics

$4.87

-0.11 (-2.21%)

04:55
06/20/18
06/20
04:55
06/20/18
04:55

Aptevo Therapeutics management to meet with Roth Capital

Meetings to be held in New York on June 19 and in Minneapolis on June 20 hosted by Roth Capital.

  • 20

    Jun

APVO Aptevo Therapeutics
$4.87

-0.11 (-2.21%)

10/05/17
PIPR
10/05/17
INITIATION
Target $6
PIPR
Overweight
Aptevo Therapeutics resumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff resumed coverage of Aptevo Therapeutics with an Overweight rating and $6 price target. The analyst sees the company creating value by growing IXINITY Factor IX sales for Hemophilia B, advancing otlertuzumab in chronic lymphocytic leukemia and its bispecific antibody pipeline.
04/11/18
ROTH
04/11/18
INITIATION
Target $12
ROTH
Buy
Aptevo Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Aptevo Therapeutics with a Buy rating and $12 price target as he believes it remains under the Street's radar with a clinical and commercial pipeline, as well as a versatile technology platform enabling growth in new directions. The analyst believes that two ongoing clinical programs may provide dynamic catalysts for the near/medium term, while the technology platform with two pending INDs provides fundamental depth to future value.
04/11/18
ROTH
04/11/18
INITIATION
Target $12
ROTH
Buy
Aptevo Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Aptevo Therapeutics with a Buy rating and $12 price target, as he believes its two ongoing clinical programs may provide catalysts for the near- to medium-term while its two pending INDs provide depth to future value.
05/10/18
PIPR
05/10/18
NO CHANGE
PIPR
Aptevo Therapeutics price target raised to $9 from $6 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Aptevo Therapeutics and raised his price target on Aptevo shares to $9 from $6 after Q1 prophylactic Hemophilia B therapy Ixinity sales of $4.1M beat Piper's $3M estimate. Additionally, the firm is increasing its FY18 Ixinity sales forecast to $18M.

TODAY'S FREE FLY STORIES

WFT

Weatherford

$0.79

-0.0263 (-3.21%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
Options
10.1K Weatherford Mar 1 calls trade as shares drop 2c to 80c »

10.1K Weatherford Mar 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

10:40
02/21/19
02/21
10:40
02/21/19
10:40
General news
Treasury Action: yields have cheapened despite some disappointing data »

Treasury Action: yields…

KAR

KAR Auction

$48.30

1.56 (3.34%)

10:37
02/21/19
02/21
10:37
02/21/19
10:37
Upgrade
KAR Auction rating change  »

KAR Auction upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

NCLH

Norwegian Cruise Line

$55.71

1.99 (3.70%)

10:32
02/21/19
02/21
10:32
02/21/19
10:32
Recommendations
Norwegian Cruise Line analyst commentary  »

Buckingham says backdrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

BSX

Boston Scientific

$40.03

-0.1 (-0.25%)

10:30
02/21/19
02/21
10:30
02/21/19
10:30
Options
Bullish option flow in Boston Scientific »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

SNPS

Synopsys

$100.68

-2.3 (-2.23%)

10:26
02/21/19
02/21
10:26
02/21/19
10:26
Recommendations
Synopsys analyst commentary  »

Synopsys weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 03

    Mar

  • 08

    Mar

  • 14

    Mar

  • 17

    Mar

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

NWL

Newell Brands

$17.18

0.05 (0.29%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Periodicals
Newell Brands CEO faces board pressure following poor sales, WSJ reports »

Newell Brands CEO Michael…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley consumer goods analysts to hold analyst/industry conference call »

Executive Director of…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

, ESALY

Eisai

$0.00

(0.00%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan large-cap biotech analysts to hold an analyst/industry conference call »

Large Cap Biotech Analyst…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan retail analysts to hold an analyst/industry conference call »

Retail Analysts Boss and…

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

EEM

iShares MSCI Emerging Markets ETF

$42.48

-0.175 (-0.41%)

10:20
02/21/19
02/21
10:20
02/21/19
10:20
Options
Size three-way spread in iShares Emerging Markets Fund as shares tick lower »

Size three-way spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
02/21/19
02/21
10:17
02/21/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
02/21/19
02/21
10:16
02/21/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
U.S. leading index dipped 0.1% to 111.3 in January »

U.S. leading index dipped…

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
Breaking General news story  »

Week of 2/15 EIA Natural…

HOME

At Home Group

$23.84

0.01 (0.04%)

, HLIT

Harmonic

$5.51

0.19 (3.57%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

HOME

At Home Group

$23.84

0.01 (0.04%)

HLIT

Harmonic

$5.51

0.19 (3.57%)

ATKR

Atkore

$24.08

-0.09 (-0.37%)

BTX

BioTime

$1.24

0.08 (6.90%)

VRCA

Verrica Pharmaceuticals

$10.99

(0.00%)

APHA

Aphria

$10.40

0.24 (2.36%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$6.11

0.13 (2.17%)

CGC

Canopy Growth

$45.44

-0.74 (-1.60%)

ACB

Aurora Cannabis

$7.18

0.12 (1.70%)

TLRY

Tilray

$80.25

-0.82 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

  • 18

    Mar

GRMN

Garmin

$82.02

-1 (-1.20%)

, BIIB

Biogen

$324.13

-10.88 (-3.25%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

GRMN

Garmin

$82.02

-1 (-1.20%)

BIIB

Biogen

$324.13

-10.88 (-3.25%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

DHI

D.R. Horton

$39.91

0.04 (0.10%)

LEN

Lennar

$49.12

0.16 (0.33%)

GIS

General Mills

$46.68

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    May

CAJ

Canon

$29.10

-0.02 (-0.07%)

, SAM

Boston Beer

$302.00

34.05 (12.71%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

CAJ

Canon

$29.10

-0.02 (-0.07%)

SAM

Boston Beer

$302.00

34.05 (12.71%)

X

U.S. Steel

$24.25

0.25 (1.04%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

AAN

Aaron's

$54.10

0.46 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$18.86

-0.57 (-2.93%)

10:10
02/21/19
02/21
10:10
02/21/19
10:10
Options
Put buyers in Kemet Corp as shares slip »

Put buyers in Kemet Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
02/21/19
02/21
10:10
02/21/19
10:10
General news
U.S. existing home sales dropped 1.2% in January to 4.94 M »

U.S. existing home sales…

CPRX

Catalyst Pharmaceuticals

$2.80

0.04 (1.45%)

10:08
02/21/19
02/21
10:08
02/21/19
10:08
On The Fly
Catalyst Pharmaceuticals defends pricing for Firdapse after Sanders slams company »

Nearly three weeks after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
Leading Indicators data reported »

January Leading…

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
FX Action: The dollar »

FX Action: The dollar was…

10:03
02/21/19
02/21
10:03
02/21/19
10:03
General news
Existing Home Sales data reported »

January Existing Home…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.